AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31377534 — intervention group
Group type: COMPARATOR
Intervention: Control (business as usual)
Number of subjects: 2172
Study 27484097 — intervention group
Group type: EXPERIMENTAL
Intervention: STNM01 (2.5nM, 25nM, 250nM)
Number of subjects: 18
Study 27484097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27484097 — intervention group
Group type: EXPERIMENTAL
Intervention: STNM01
Number of subjects: 18
Study 26051530 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI plus stepwise ablation
Number of subjects: 150
Study 26051530 — intervention group
Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 150
Study 26051530 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise ablation
Number of subjects: 150
Study 24098633 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition-specific home exercises combined with advice and education
Number of subjects: 0
Study 24098633 — intervention group
Group type: COMPARATOR
Intervention: Advice and education alone (Control)
Number of subjects: 0
Study 22078153 — intervention group
Group type: EXPERIMENTAL
Intervention: LDA plus naproxen/esomeprazole magnesium (500 mg naproxen and 20 mg esomeprazole magnesium, twice daily on days 6-10)
Number of subjects: 42
Study 22078153 — intervention group
Group type: COMPARATOR
Intervention: LDA plus placebo (81 mg LDA once daily on days 1-5 and placebo twice daily on days 6-10)
Number of subjects: 42
Study 22078153 — intervention group
Group type: COMPARATOR
Intervention: LDA plus placebo
Number of subjects: 42
Study 22078153 — intervention group
Group type: EXPERIMENTAL
Intervention: LDA plus naproxen/esomeprazole magnesium
Number of subjects: 42
Study 20146880 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM + BCG
Number of subjects: 87
Study 20146880 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 87
Study 17592345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 78
Study 17592345 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 78
Study 15187778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented formula (NT+)
Number of subjects: 30
Study 15187778 — intervention group
Group type: COMPARATOR
Intervention: Formula without nucleotides (NT-)
Number of subjects: 30
Study 15187778 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 30
Study 11289473 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2,550 mg/day for 14 days)
Number of subjects: 10
Study 11289473 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated obese subjects)
Number of subjects: 10
Study 11289473 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (0.1-0.5 microg/ml) in pooled human plasma
Number of subjects: 10
Study 9142611 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review feedback program during the guideline period
Number of subjects: 446
Study 9142611 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review feedback program during the one-year follow-up period
Number of subjects: 446
Study 9142611 — intervention group
Group type: COMPARATOR
Intervention: Preguideline period
Number of subjects: 446
Study 7634320 — intervention group
Group type: EXPERIMENTAL
Intervention: De Vega's suture annuloplasty
Number of subjects: 48
Study 7634320 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) guidance during De Vega's annuloplasty
Number of subjects: 48
Study 7634320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative assessment by TEE
Number of subjects: 48
Study 2792096 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Labat's technique
Number of subjects: 224
Study 2792096 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative technique (intersection of hiatus-trochanteric line)
Number of subjects: 224
Study 1080961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous high dose methotrexate and leucovorin rescue
Number of subjects: 60
Study 1080961 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 60
Study 31465401 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-focus compressive sensing (CS) method for 3-D and random-access TPE microscopy using a digital micromirror device (DMD)
Number of subjects: 0
Study 31465401 — intervention group
Group type: EXPERIMENTAL
Intervention: CS algorithms for reconstructing 3-D images
Number of subjects: 0
Study 28557555 — intervention group
Group type: EXPERIMENTAL
Intervention: β1 blocker nebivolol
Number of subjects: 0
Study 28557555 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 26685397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cellulose powder
Number of subjects: 36
Study 26685397 — intervention group
Group type: COMPARATOR
Intervention: Physiological sea water
Number of subjects: 36
Study 23140546 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment in current smokers (n=129)
Number of subjects: 1600
Study 23140546 — intervention group
Group type: COMPARATOR
Intervention: Patients not on statins (n=720)
Number of subjects: 1600
Study 21287255 — intervention group
Group type: EXPERIMENTAL
Intervention: FaceSay computer-based social skills training program
Number of subjects: 49
Study 19543892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical TFESI using triamcinolone (particulate steroid)
Number of subjects: 159
Study 19543892 — intervention group
Group type: COMPARATOR
Intervention: Cervical TFESI using dexamethasone (non-particulate steroid)
Number of subjects: 159
Study 19543892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical TFESI (general)
Number of subjects: 159
Study 19543892 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous operation
Number of subjects: 159
Study 22392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Peach shake meal (PSM) (SA: 0.06 ± 0.001 mg/100 g)
Number of subjects: 26
Study 22392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Peach shake meal (PSM)
Number of subjects: 26
Study 22392497 — intervention group
Group type: COMPARATOR
Intervention: Mixed sugar meal (MSM)
Number of subjects: 26
Study 15774433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT), 12-14 sessions
Number of subjects: 30
Study 15774433 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 30
Study 15774433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 30
Study 12005157 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-min vibration intervention
Number of subjects: 16
Study 12005157 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 16
Study 9469276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical oxytocin (20 IU in 20 mL of saline)
Number of subjects: 81
Study 9469276 — intervention group
Group type: COMPARATOR
Intervention: Intraumbilical saline (20 mL)
Number of subjects: 81
Study 8535640 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sulphasalazine (SASP) and methotrexate (MTX)
Number of subjects: 40
Study 8535640 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 40
Study 2404049 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention (15% of energy intake) with bi-weekly individual counseling sessions
Number of subjects: 17
Study 2404049 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 17
Study 389817 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimazine
Number of subjects: 0
Study 389817 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin
Number of subjects: 0
Study 11483335 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation (goserelin 3.6 mg every 4 weeks and flutamide 250 mg t.i.d. for 2 months before and during radiation therapy)
Number of subjects: 456
Study 11483335 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation (goserelin and flutamide)
Number of subjects: 456
Study 11483335 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen ablation (goserelin and flutamide) in patients with Gleason score 2‐‐6
Number of subjects: 456
Study 11483335 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 456
Study 31348227 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise program (12 weeks duration)
Number of subjects: 94
Study 31348227 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific exercises performed at home
Number of subjects: 94
Study 28682136 — intervention group
Group type: EXPERIMENTAL
Intervention: Social intervention group
Number of subjects: 222
Study 28682136 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 222
Study 27439975 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy limited to the mesorectum
Number of subjects: 302
Study 27439975 — intervention group
Group type: COMPARATOR
Intervention: Standard completion total mesorectal excision (TME)
Number of subjects: 302
Study 23429621 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol (BTFC)
Number of subjects: 80
Study 23429621 — intervention group
Group type: COMPARATOR
Intervention: Travoprost/timolol (TTFC)
Number of subjects: 80
Study 22035851 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg)
Number of subjects: 49
Study 22035851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg)
Number of subjects: 49
Study 21225011 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseasonal prophylactic treatment with antihistamines (2-4 weeks before pollen season)
Number of subjects: 0
Study 21225011 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 16904960 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 70
Study 16904960 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 70
Study 15784793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-screening assessment
Number of subjects: 3535
Study 15784793 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-screening assessment
Number of subjects: 3535
Study 15784793 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 3535
Study 12486618 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily
Number of subjects: 24
Study 12486618 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy
Number of subjects: 24
Study 9869174 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched in monounsaturated fat (MUFA) for 3 weeks
Number of subjects: 12
Study 9869174 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-enriched control diet
Number of subjects: 12
Study 7637479 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 630
Study 7637479 — intervention group
Group type: COMPARATOR
Intervention: Injected polio vaccine (IPV)
Number of subjects: 630
Study 2491766 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids plus thyrotropin-releasing hormone (TRH)
Number of subjects: 0
Study 2491766 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 870513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovine prolactin (25 mg)
Number of subjects: 8
Study 870513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ml normal saline)
Number of subjects: 8
Study 870513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovine prolactin (100 mg)
Number of subjects: 8
Study 30041576 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based measures of cell phone use while driving
Number of subjects: 16
Study 27020911 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% articaine
Number of subjects: 95
Study 27020911 — intervention group
Group type: COMPARATOR
Intervention: 4% articaine
Number of subjects: 95
Study 26666324 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel oral anticoagulants (NOACs) including dabigatran etexilate, rivaroxaban, apixaban, and edoxaban.
Number of subjects: 0
Study 26666324 — intervention group
Group type: COMPARATOR
Intervention: Classic anticoagulants like heparin, low‐molecular‐weight heparins (LMWHs), fondaparinux, and vitamin K antagonists.
Number of subjects: 0
Study 24037563 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard verbal feedback plus video (group 1)
Number of subjects: 48
Study 24037563 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal feedback alone (group 2)
Number of subjects: 48
Study 21199290 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg sublingual misoprostol
Number of subjects: 49
Study 21199290 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 49
Study 21199290 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mcg sublingual misoprostol
Number of subjects: 49
Study 21199290 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin (10 IU)
Number of subjects: 49
Study 18635671 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling advice and education
Number of subjects: 60
Study 18635671 — intervention group
Group type: COMPARATOR
Intervention: Routine care (no specific kneeling advice)
Number of subjects: 60
Study 16409193 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen tablet (SQ-T) at various doses (25,000 to 1,000,000 standardized quality tablet)
Number of subjects: 12
Study 16409193 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen tablet (SQ-T)
Number of subjects: 12
Study 16409193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12744860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (5 doses)
Number of subjects: 505
Study 12744860 — intervention group
Group type: COMPARATOR
Intervention: Whole‐cell pertussis vaccine (5 doses)
Number of subjects: 505
Study 10561296 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m(2) every 3 weeks
Number of subjects: 326
Study 10561296 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m(2) every 3 weeks
Number of subjects: 326
Study 8739678 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% once daily (morning dose)
Number of subjects: 31
Study 8739678 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% once daily (evening dose)
Number of subjects: 31
Study 8739678 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5% twice daily
Number of subjects: 31
Study 1820640 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day regimen of oral artesunate at 600 mg
Number of subjects: 89
Study 1820640 — intervention group
Group type: COMPARATOR
Intervention: 5-day regimen of oral artesunate at 600 mg
Number of subjects: 89
Study 6755786 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg and placebo
Number of subjects: 49
Study 6755786 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and dipyridamole (DIP) 325 mg and 75 mg
Number of subjects: 49
Study 6755786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 6755786 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) alone
Number of subjects: 49
Study 6755786 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and dipyridamole (DIP)
Number of subjects: 49
Study 31361815 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messages (twice-daily) over 6 months
Number of subjects: 95
Study 31361815 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual for 6 months
Number of subjects: 95
Study 29032666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg
Number of subjects: 75
Study 29032666 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 75
Study 25933913 — intervention group
Group type: EXPERIMENTAL
Intervention: New CPAP
Number of subjects: 28
Study 25933913 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-level PAP
Number of subjects: 28
Study 25933913 — intervention group
Group type: COMPARATOR
Intervention: Subjective and objective measures of sleepiness
Number of subjects: 28
Study 23102885 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis group (TG) - low-dose tissue plasminogen activator plus anticoagulation (n=61)
Number of subjects: 121
Study 23102885 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - anticoagulation alone (n=60)
Number of subjects: 121
Study 21689098 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive of U.S.$20 to bring in the intervention letter to their provider
Number of subjects: 54
Study 21689098 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 54
Study 17607304 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 0
Study 17607304 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant androgen deprivation therapy
Number of subjects: 0
Study 16876666 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous haemodiafiltration
Number of subjects: 360
Study 16876666 — intervention group
Group type: COMPARATOR
Intervention: Intermittent haemodialysis
Number of subjects: 360
Study 12627042 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol
Number of subjects: 56
Study 12627042 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 56
Study 12627042 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 56
Study 10704610 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent vasodilatation
Number of subjects: 71
Study 10704610 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-independent vasodilatation
Number of subjects: 71
Study 10704610 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD)
Number of subjects: 71
Study 10704610 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of FMD
Number of subjects: 71
Study 9625844 — intervention group
Group type: EXPERIMENTAL
Intervention: Val/Val genotype
Number of subjects: 57
Study 9625844 — intervention group
Group type: COMPARATOR
Intervention: Other genotypes (Ala/Ala and Ala/Aal)
Number of subjects: 57
Study 7875267 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 13
Study 7875267 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 13
Study 7875267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2827456 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (30 g added to formula meal)
Number of subjects: 6
Study 2827456 — intervention group
Group type: EXPERIMENTAL
Intervention: California small white beans
Number of subjects: 6
Study 2827456 — intervention group
Group type: EXPERIMENTAL
Intervention: PteGlu (1.13 mumol)
Number of subjects: 6
Study 2827456 — intervention group
Group type: EXPERIMENTAL
Intervention: PteGlu7 (1.13 mumol)
Number of subjects: 6
Study 28809383 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose α-galactosidase (300 GALU)
Number of subjects: 31
Study 28809383 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose α-galactosidase (150 GALU)
Number of subjects: 31
Study 28809383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 31
Study 28137316 — intervention group
Group type: EXPERIMENTAL
Intervention: time‐intensive cognitive‐behaviour therapy (iCBT)
Number of subjects: 34
Study 28137316 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 34
Study 28137316 — intervention group
Group type: COMPARATOR
Intervention: healthy control group
Number of subjects: 34
Study 25639732 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestalt and lucid dreaming group therapy (LDG)
Number of subjects: 32
Study 25639732 — intervention group
Group type: COMPARATOR
Intervention: Gestalt therapy group (GTG)
Number of subjects: 32
Study 23061978 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI-guided fluid management
Number of subjects: 21
Study 23061978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 19766503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow, low-resistance (HFLR) technique
Number of subjects: 48
Study 19766503 — intervention group
Group type: COMPARATOR
Intervention: Normal-flow technique
Number of subjects: 48
Study 18374458 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil (10 mL, 3 times a day for 14 days)
Number of subjects: 38
Study 18374458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 mL, 3 times a day for 14 days)
Number of subjects: 38
Study 16685542 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical furosemide (6.6 mmol/l solution)
Number of subjects: 40
Study 16685542 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone (1 mg/kg/day)
Number of subjects: 40
Study 16685542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 12404674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan Depletion (TD)
Number of subjects: 13
Study 12404674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine Depletion (TPD)
Number of subjects: 13
Study 12404674 — intervention group
Group type: COMPARATOR
Intervention: Balanced-Control Condition (B)
Number of subjects: 13
Study 9539519 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 199
Study 9539519 — intervention group
Group type: COMPARATOR
Intervention: Boluses of meperidine
Number of subjects: 199
Study 7840074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri (ADH)
Number of subjects: 33
Study 7840074 — intervention group
Group type: COMPARATOR
Intervention: Streptococcus thermophilus and Lactobacillus bulgaricus
Number of subjects: 33
Study 1982576 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 113
Study 1982576 — intervention group
Group type: COMPARATOR
Intervention: Cephradine combined with metronidazole
Number of subjects: 113
Study 366741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline
Number of subjects: 10
Study 366741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg terbutaline
Number of subjects: 10
Study 366741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10